Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest from Adam Zamecnik
Adding to five new clinical trials launched in 2024, Xentria is doubling down on its ambitions in the biosimilars arena with up to six further studies in the coming year.
Rounding up another important year in the fight against HIV, the MPP’s executive director Charles Gore speaks to Generics Bulletin about the organization’s biggest milestones in the past 12 months.
The two companies have signed a co-development agreement focused on the potential creation of new long-acting injectable therapies for psychiatric conditions for an undisclosed financial sum.
A few months after a positive Phase III trial readout, Henlius has filed an application for its Organon-partnered Perjeta biosimilar in its domestic Chinese market.
Following its recent presentation of results for the third quarter of the 2024 fiscal year, Organon’s US biosimilars lead Jon Martin spoke to Generics Bulletin about the company’s adalimumab plans and strategy with upcoming launches, as well as how these will benefit from the firm’s focus on women’s health.
Hikma aims to launch fewer, but more material, products in the coming years as part of a shift in its research and development strategy that was discussed in a Q&A at this year’s Jefferies Healthcare Conference.